RenovoRx Achieves Key Phase III Milestone in TIGeR-PaC Trial, Exceeds 100 Randomized Patients, and Remains on Track for Enrollment Completion.
ByAinvest
Thursday, Mar 26, 2026 8:32 am ET1min read
RNXT--
RenovoRx has surpassed 100 randomized patients in its Phase III TIGeR-PaC trial, with enrollment completion expected in H1 2026 and final data in 2027. The trial evaluates intra-arterial gemcitabine delivered via RenovoCath for locally advanced pancreatic cancer. Select TIGeR-PaC cancer centers have begun using the RenovoCath device for targeted drug delivery in solid tumors.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet